Paper Details

  1. Home
  2. Paper Details

[Treatment of highly resistant germs by dibekacin in patients with urinary tract infections (author's transl)].

Author: PetersH J

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Dibekacin, an aminoglycoside, effectively treated highly resistant germs in 45 patients. It eliminated 41 out of 55 primary sensitive germs, including 6 out of 11 Pseudomonas germs. The drug showed minimal nephrotoxic side effects and no evidence of damage to the VIIIth brain nerve. Dibekacin is a viable alternative to gentamicin.
Paper Details　
Original Abstract of the Article :
The aminoglycoside dibekacin, developed in Japan and now on the market in Germany, has been tested for its clinical and microbiological effectiveness on 45 patients with highly resistant germs. 41 of the 55 primary sensitive germs could be thus eliminated from the urine, 6 of the 11 being pseudomona...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/470791

データ提供：米国国立医学図書館（NLM）

Dibekacin: A New Weapon in the Fight Against Resistant Infections

This research examines the efficacy of dibekacin, a new aminoglycoside antibiotic, in treating urinary tract infections caused by highly resistant bacteria. The authors studied a group of patients with these infections to assess the drug's effectiveness and side effects.

Imagine a caravan crossing a desert landscape, where some of the camels are infected with a stubborn disease resistant to traditional remedies. This research explores the potential of a new antibiotic, dibekacin, to combat this persistent threat.

A Promising New Antibiotic

The study found that dibekacin effectively eliminated resistant bacteria from the urine in a significant proportion of patients. This finding suggests that dibekacin may be a valuable tool for treating infections caused by multi-drug resistant bacteria, a growing concern in healthcare.

Navigating the Desert of Antimicrobial Resistance

This research underscores the importance of developing new antibiotics to combat the growing threat of antimicrobial resistance. It highlights the need for continued research and innovation to ensure that we have effective treatments for infections. It's a reminder that the desert of antimicrobial resistance is vast and challenging, and we need to be proactive in our search for new solutions.

Dr.Camel's Conclusion

This research provides a glimmer of hope in the fight against antimicrobial resistance. Dibekacin offers a promising new weapon in our arsenal against resistant infections. It's a reminder that while the desert of antimicrobial resistance may seem vast and daunting, we can continue to find new oases of hope and healing.

Date :
  1. Date Completed 1979-10-24
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

470791

DOI: Digital Object Identifier

470791

Related Literature

Article Analysis
・Effective treatment of germs
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.